Kikuchi-Fujimoto Disease, A Possible Complication of Rituximab Treatment
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Rituximab, a chimeric anti-CD20 IgG1 monoclonal antibody, has been used as a rescue therapy for steroid-dependent or refractory nephrotic syndrome. However, the adverse effects of rituximab are yet to be investigated. We report a case of a 9-year-old boy with steroid-dependent nephrotic syndrome who developed Kikuchi-Fujimoto disease after several cycles of rituximab therapy. Kikuchi-Fujimoto disease is a benign, self-limited necrotizing histiocytic lymphadenitis of unknown etiology. In the present case, Kikuchi-Fujimoto disease developed when the peripheral blood B-cell count of the patient was at nadir, and the lesion regressed slowly but spontaneously after recovery of the B-cell count. To our knowledge, although the pathologic diagnosis of Kikuchi-Fujimoto disease was unavailable, this is the first report of Kikuchi-Fujimoto disease with clinical diagnosis as a possible adverse effect of rituximab.
Abstract
Rituximab, a chimeric anti-CD20 IgG1 monoclonal antibody, has been used as a rescue therapy for steroid-dependent or refractory nephrotic syndrome. However, the adverse effects of rituximab are yet to be investigated. We report a case of a 9-year-old boy with steroid-dependent nephrotic syndrome who developed Kikuchi-Fujimoto disease after several cycles of rituximab therapy. Kikuchi-Fujimoto disease is a benign, self-limited necrotizing histiocytic lymphadenitis of unknown etiology. In the present case, Kikuchi-Fujimoto disease developed when the peripheral blood B-cell count of the patient was at nadir, and the lesion regressed slowly but spontaneously after recovery of the B-cell count. To our knowledge, although the pathologic diagnosis of Kikuchi-Fujimoto disease was unavailable, this is the first report of Kikuchi-Fujimoto disease with clinical diagnosis as a possible adverse effect of rituximab.
참고문헌 (11)
- Kimby E, "Tolerability and safety of rituximab (MabThera)", Cancer Treat Rev, 31, pp.456~473 (2005)
- Liossis SN, "Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells", Clin Immunol, 127, pp.280~285 (2008)
- Iijima K, "Rituximab for childhood refractory nephrotic syndrome", Pediatr Int, 53, pp.617~621 (2011)
- Liote H, "Rituximab-induced lung disease: a systematic literature review", Eur Respir J, 35, pp.681~687 (2010)
- Ardelean DS, "Severe ulcerative colitis after rituximab therapy", Pediatrics, 126, pp.243~246 (2010)
- Parajuli R, "Rituximab-induced acute severe thrombocytopenia", Br J Haematol, 149, pp.804~ (2010)
- Hutchinson CB, "Kikuchi-Fujimoto disease", Arch Pathol Lab Med, 134, pp.289~293 (2010)
- Lee BC, "Kikuchi.Fujimoto disease: a 15-year analysis at a children’s hospital in the United States", Clin Pediatr (2012)
- Kwon SY, "CT findings in Kikuchi disease: analysis of 96 cases", AJNR Am J Neuroradiol, 25, pp.1099~1102 (2004)
- Lee S, "Kikuchi Disease: Differentiation from Tuberculous Lymphadenitis Based on Patterns of Nodal Necrosis on CT", AMERICAN JOURNAL OF NEURORADIOLOGY, 33(1), pp.135~140 (2012), AMER SOC NEURORADIOLOGY
- Stasi R, "Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura", Blood, 110, pp.2924~2930 (2007)